Improving Stability with Advanced Therapies in Parkinson’s Disease

In this episode, ‘Improving Stability with Advanced Therapies in Parkinson’s Disease,’ the panelists discuss the transition to continuous subcutaneous apomorphine infusion and its role in managing OFF time. The expert neurologist explains how advanced therapies can provide more consistent dopaminergic stimulation, helping to reduce motor fluctuations and improve symptom control. The clinician emphasizes that treatment goals extend beyond reducing OFF time to achieving more predictable daily functioning and enhancing overall quality of life.

The patient discussed that this transition led to greater reliability and confidence in daily activities. They describe fewer disruptions from OFF periods, allowing for improved planning and increased participation in family events and routines. Physical function, including balance and exercise capacity, also improved, along with a reduced need for frequent oral medication adjustments. Family members and others noticed these changes, reinforcing the impact of optimized therapy on both visible symptoms and overall functioning.

The discussion also highlights the importance of caregiver involvement and structured symptom tracking. The patient shares how a care partner played a critical role in identifying subtle changes in symptoms that might otherwise go unnoticed. The clinician notes that tools such as symptom diaries, targeted questioning, and patient-recorded videos can help differentiate symptoms and guide treatment decisions. The patient and clinician collectively emphasize that collaboration and proactive management are essential to improving long-term outcomes in Parkinson’s disease.

The next episode in this series, ‘Recognizing and Treating OFF Time in Parkinson’s Disease,’ features the panelists discussing the importance of early recognition and proactive management of OFF time in Parkinson’s disease. The conversation highlights the need for strong communication and patient advocacy to improve outcomes.